Skip to main content
SpringerLink
Log in

Central imidazoline receptors as a target for centrally acting antihypertensive drugs

  • Reviews
  • Published:
Pharmacy World and Science Aims and scope Submit manuscript

Abstract

Imidazoline (I1)-receptors in the central nervous system play a role in the central regulation of blood pressure and heart rate. Stimulation of these receptors in the rostral ventrolateral medulla induces peripheral sympathoinhibition, and hence a reduction of elevated blood pressure. The imidazoline derivatives moxonidine and rilmenidine are moderately selective I1 receptor stimulants which have been introduced as centrally acting antihypertensives. Since they have little affinity for α2-adrenoceptors, they may be expected to cause less sedation and dry mouth than the α2-adrenoceptor agonists clonidine and methyldopa. The concept of I1 receptors and their agonists therefore offers the possibility to develop centrally acting antihypertensives with a more favourable profile of adverse reactions than the classical α2-adrenoceptor stimulants such as clonidine and methyldopa.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Van Zwieten PA, Thoolen MJMC, Timmermans PBMWM. The hypotensive activity and side-effects of methyldopa, clonidine and guanfacine. Hypertension 1984;6 Suppl 11: 28–33.

    Google Scholar 

  2. Van Zwieten PA, Thoolen MJMC, Timmermans PBMWM. The pharmacological base of the hypotensive activity and side-effects of α-methyl-DOPA, clonidine and guanfacine. Hypertension 1984;6:11–28.

    Google Scholar 

  3. Van Zwieten PA. Overview of α2-adrenoceptor agonists with a central action. Am J Cardiol 1986;57:3E-5E.

    PubMed  Google Scholar 

  4. Van Zwieten PA. Different types of centrally acting anti-hypertensive drugs. Eur Heart J 1992;13 Suppl A:18–21.

    PubMed  Google Scholar 

  5. Van Zwieten PA, Chalmers JP. Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc Drugs Ther 1994;8:787–99.

    PubMed  Google Scholar 

  6. Sen S, Tarazi RC, Bumpus FM. Cardiac hypertrophy and anti-hypertensive therapy. Cardiovasc Res 1977;11:427–33.

    PubMed  Google Scholar 

  7. Henning M. α-methyl-DOPA and related compounds. In: Van Zwieten PA, editor. Handbook of hypertension. Vol. 3. Pharmacology of antihypertensive drugs. Amsterdam: Elsevier, 1984:154–93.

    Google Scholar 

  8. Ernsberger P, Giuliano R, Willette RN, Reid DJ. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990;253:408–18.

    PubMed  Google Scholar 

  9. Feldman J, Tiberiça E, Bricca G, Dontenwill M, Belcourt A, Bousquet P. Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit. Br J Pharmacol 1990;100:600–4.

    PubMed  Google Scholar 

  10. Haxhiu MA, Dreshaj I, Schäfer SG, Ernsberger P. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1994;24 Suppl 1:S1–8.

    Google Scholar 

  11. Michel MC, Ernsberger P. Keeping an eye on the I site: imidazoline-preferring receptors. Trends Pharmacol Sci 1992;13:369–70.

    PubMed  Google Scholar 

  12. Gomez RE, Ernsberger P, Feinland G, Reis D. Rilmenidine lowers arterial pressure via imidazoline receptors in brain stem C1 area. Eur J Pharmacol 1991;195:181–91.

    PubMed  Google Scholar 

  13. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ. Agmatine: an endogenous ‘clonidine-displacing’ substance in the brain. Science 1994;263:966–9.

    PubMed  Google Scholar 

  14. Head GA, Saunajust F. Importance of imidazoline receptors in the cardiovascular response to clonidine and rilmenidine in conscious rabbits. Fundam Clin Pharmacol 1992;6 Suppl D:31S-4S.

    PubMed  Google Scholar 

  15. Tibiriça E, Feldman J, Mermet C, Gonon F, Bousquet P. An imidazoline specific mechanism for the hypotensive effect of clonidine: a study with yohimbine and idazoxan. J Pharmacol Exp Ther 1991;256:606–13.

    PubMed  Google Scholar 

  16. Timmermans PBMWM, van Zwieten PA. α-Adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem 1982;25:1389–401.

    PubMed  Google Scholar 

  17. Ernsberger P, Damon TH, Graff LM, Schäfer SG, Christen MO. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther 1993;264:172–82.

    PubMed  Google Scholar 

  18. Michel MC, Insel PA. Are there multiple imidazoline binding sites?Trends Pharmacol Sci 1989;10:342–4.

    PubMed  Google Scholar 

  19. Ollivier JP, Christen MO. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience. J Cardiovasc Pharmacol 1994;24 Suppl 1:S39–48.

    Google Scholar 

  20. Prichard BNC. Clinical experience with moxonidine. Cardiovasc Drugs Ther 1994, 8:49–58.

    PubMed  Google Scholar 

  21. Ernsberger P, Westbrooks KL, Christen MO, Schäfer SG. A second generation of centrally acting antihypertensives acts on putative I1-imidazoline receptors. J Cardiovasc Pharmacol 1992;20 Suppl 4:S1–10.

    Google Scholar 

  22. Chrisp P, Faulds D. Moxonidine. Drugs 1992;44:993–1012.

    Google Scholar 

  23. Dollery CT. Rilmenidine in mild to moderate hypertension. A double-blind, randomised, parallel group multicenter comparison with methyldopa in 157 patients. Curr Ther Res 1990;47:194–221.

    Google Scholar 

  24. Harron DWG. Clinical pharmacology of imidazolines and related compounds. Fundam Clin Pharmacol 1992;6 Suppl 1:41S-4S.

    PubMed  Google Scholar 

  25. Parini A, Bousquet P. From α2-adrenoceptors to imidazoline preferring receptors. Fundam Clin Pharmacol 1992;6 Suppl 1:1S-63S.

    Google Scholar 

  26. Motz W, Strauer BE. Therapy of hypertensive cardiac hypertrophy and impaired coronary microcirculation. J Cardiovasc Pharmacol 1994;24 Suppl 1:S34–8.

    PubMed  Google Scholar 

  27. Weitzel G, Pfeiffer B, Stock W. Insulin-like partial effects of agmatine derivatives in adipocytes. Hoppe Seyler's Z Physiol Chem 1980;361:51–60.

    PubMed  Google Scholar 

  28. Kaan EC, Brückner R, Frohly P, Tulp M, Schäfer SG, Zügler D. Effects of agmatine and moxonidine on glucose metabolism. Cardiovasc Risk Factors 1995. In press.

Download references

Author information

Authors and Affiliations

  1. Departments of Pharmacotherapy and Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105, AZ Amsterdam, the Netherlands

    P. A. van Zwieten

Authors
  1. P. A. van Zwieten
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Zwieten, P.A. Central imidazoline receptors as a target for centrally acting antihypertensive drugs. Pharm World Sci 17, 186–190 (1995). https://doi.org/10.1007/BF01870609

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01870609

Keywords

Search

Navigation